ELsayed hammad

Dr. ELsayed hammad

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SAShaimaa Abdelaziz Abdelmoneim
Shaimaa Abdelaziz Abdelmoneim
Malik SallamMalik Sallam
Malik Sallam
DHDina Hafez
Dina Hafez
EEEhab Elrewany
Ehab Elrewany
HMHesham Metwalli Mousli
Hesham Metwalli Mousli
Ramy Mohamed GhazyRamy Mohamed Ghazy
Ramy Mohamed Ghazy
The World Health Organization (WHO) recommended coronavirus disease 2019 (COVID-19) booster dose vaccination after completing the primary vaccination series for individuals ≥18 years and most-at-risk populations. This study aimed to estimate the pooled proportion of COVID-19 vaccine booster dose uptake and intention to get the booster dose among general populations and healthcare workers (HCWs). We searched PsycINFO, Scopus, EBSCO, MEDLINE Central/PubMed, ProQuest, SciELO, SAGE, Web of Science, Google Scholar, and ScienceDirect according to PRISMA guidelines. From a total of 1079 screened records, 50 studies were extracted. Meta-analysis was conducted using 48 high-quality studies according to the Newcastle-Ottawa Scale quality assessment tool. Using the 48 included studies, the pooled proportion of COVID-19 vaccine booster dose acceptance among 198,831 subjects was 81% (95% confidence interval (CI): 75–85%, I2 = 100%). The actual uptake of the booster dose in eight studies involving 12,995 subjects was 31% (95% CI: 19–46%, I2 = 100%), while the intention to have the booster dose of the vaccine was 79% (95% CI: 72–85%, I2 = 100%). The acceptance of the booster dose of COVID-19 vaccines among HCWs was 66% (95% CI: 58–74%), I2 = 99%). Meta-regression revealed that previous COVID-19 infection was associated with a lower intention to have the booster dose. Conversely, previous COVID-19 infection was associated with a significantly higher level of booster dose actual uptake. The pooled booster dose acceptance in the WHO region of the Americas, which did not include any actual vaccination, was 77% (95% CI: 66–85%, I2 = 100%). The pooled acceptance of the booster dose in the Western Pacific was 89% (95% CI: 84–92%, I2 = 100), followed by the European region: 86% (95% CI: 81–90%, I2 = 99%), the Eastern Mediterranean region: 59% (95% CI: 46–71%, I2 = 99%), and the Southeast Asian region: 52% (95% CI: 43–61%, I2 = 95). Having chronic disease and trust in the vaccine effectiveness were the significant predictors of booster dose COVID-19 vaccine acceptance. The global acceptance rate of COVID-19 booster vaccine is high, but the rates vary by region. To achieve herd immunity for the disease, a high level of vaccination acceptance is required. Intensive vaccination campaigns and programs are still needed around the world to raise public awareness regarding the importance of accepting COVID-19 vaccines needed for proper control of the pandemic.

10 November 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Ramy Mohamed GhazyRamy Mohamed Ghazy
Ramy Mohamed Ghazy
EEEhab Elrewany
Ehab Elrewany
AGAssem Gebreal
Assem Gebreal
RERony Ibrahim ElMakhzangy
Rony Ibrahim ElMakhzangy
NFNoha Fadl
Noha Fadl
MHMai Hussein
Mai Hussein
Background: The variation in the reported vaccine safety and effectiveness could contribute to the high rates of vaccine hesitancy among the general population and healthcare workers in areas where monkeypox (mpox) is circulating. In this review, our objective was to evaluate the safety, immunogenicity, effectiveness, and efficacy of the mpox vaccines. Methods: An extensive search for articles across multiple databases was performed, including searching six databases (PubMed Central, PubMed Medline, Scopus, Web of Science, Cochrane, ProQuest), two pre-print databases (European PMC Preprint and MedRxiv), and Google Scholar. Results: A total of 4290 citations were retrieved from the included databases. Following the removal of duplicates and the initial screening of records, a total of 36 studies were included into the analysis. Additionally, we identified five more studies through manual searches, resulting in a total of 41 eligible articles for qualitative synthesis. The study findings revealed that mpox vaccines demonstrate the ability to generate adequate antibodies; however, their effectiveness may decrease over time, exhibiting varying safety profiles. Most of the included studies consistently reported substantial levels of effectiveness and efficacy against mpox. Interestingly, the number of vaccine doses administered was found to influence the degree of immunogenicity, subsequently impacting the overall effectiveness and efficacy of the vaccines. Furthermore, we found that smallpox vaccines exhibited a form of cross-protection against mpox. Conclusions: Vaccines can be used to prevent mpox and effectively control its spread.

28 November 2022 in Comparative Immunology, Microbiology and Infectious Diseases
Verified
Journal Article
Closed access
Ramy Mohamed GhazyRamy Mohamed Ghazy
Ramy Mohamed Ghazy
EHELsayed hammad
ELsayed hammad
MHMohamed Hall
Mohamed Hall
AMAmira Mahboob
Amira Mahboob
SZSally Zeina
Sally Zeina
MHMai Hussein
Mai Hussein

26 July 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
RERowan H. Elhalag
Rowan H. Elhalag
KMKaram R. Motawea
Karam R. Motawea
NTNesreen E. Talat
Nesreen E. Talat
SRSamah S. Rouzan
Samah S. Rouzan
NMNada Mahmoud
Nada Mahmoud
JSJaffer Shah
Jaffer Shah
Aim: The authors aimed to perform a meta-analysis to evaluate the association between herpes simplex virus (HSV) infection and the risk of developing dementia. Methods: The authors searched the following databases: PubMed, Scopus, Cochrane Library, and Web of Science. The authors included any randomized control trials and controlled observational studies that investigated the prevalence of dementia in HSV-infected patients and HSV-free control group. Also, if the studies measured the levels of HSV antibodies and incidence of these antibodies in patients with dementia compared with a healthy control group. Results: After a comprehensive literature search, 19 studies were included in the meta-analysis with 342 535 patients included in the analysis. The pooled analysis showed a statistically significant association between Alzheimer’s disease (AD), mild cognitive impairment (MCI), and increased levels of IgG titer group [mean difference (MD) = 0.99, 95% confidence interval (CI) = 0.36–1.63, P-value = 0.002], (MD = 0.80, 95% CI = 0.26–1.35, P-value = 0.004), respectively. Additionally, the generic inverse variance showed a statistically significant association between the HSV group and increased incidence of dementia compared with the no HSV control group [risk ratio (RR) = 2.23, 95% CI = 1.18–2.29, P-value <0.00001]. Moreover, this analysis showed no statistically significant difference between the AD group and the control group in anti-HSV IgM titer n (%) outcome (RR = 1.35, 95% CI = 0.91–2.01, P-value = 0.14), respectively. Conclusion: This study revealed that AD and MCI patients have increased levels of IgG antibodies titer against HSV infection. The study showed a significant association between HSV infection and increased incidence of dementia. Thus, regular follow-up of HSV patients’ IgG titer levels could be useful in the prevention of dementia in these patients.

30 December 2024 in Research Square
Verified
Preprint
Open access
PDF file
FKFezaan A. Kazi
Fezaan A. Kazi
EHELsayed hammad
ELsayed hammad
SGSalil J. Gupta
Salil J. Gupta
RKRayyan M. Khan
Rayyan M. Khan
MAMarium Ansari
Marium Ansari
AAAdeela M. Alizai
Adeela M. Alizai
Purpose There is currently a paucity of literature describing bilateral reversible disc edema as an early presenting sign of heart failure in the setting of bicuspid aortic valve disease. There is however a plethora of research indicating congenital bicuspid aortic valve (BAV) as a major risk factor for possible development of infective endocarditis in a patient’s lifetime. Observations A 26-year-old man presented with bilateral blurry vision with severe 4+ bilateral optic disc edema of one month duration and venous engorgement. The patient also complained of coughing when lying down, unintentional weight loss, joint swelling and fatigue. On further testing, the patient was found to have streptococcal bacteremia with aortic valve endocarditis, severe aortic regurgitation, congenital bicuspid aortic valve and decompensated class IV systolic heart failure. Following emergent aortic valve replacement, there was complete reversal of optic disc edema and symptomatic improvement. Conclusions and Importance Our patient’s clinical presentation demonstrates that optic disc edema can be an earlier sign of progressing heart failure and highlights the clinical progression of an increased risk of developing bacterial endocarditis for patients with BAV disease when other causes are not obvious. The life-threatening presentation of our case supports the importance of regular monitoring of valvular status and The observation of the optic disc edema and investigate the cause.

26 December 2024 in Clinical Cardiology
Verified
Journal Article
Open access
AGAhmed M. Gazer
Ahmed M. Gazer
EHELsayed hammad
ELsayed hammad
We recently reviewed the article titled “Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation” published in Clinical Cardiology by [khan et al.] (1) with great interest. This study addresses a crucial area of clinical practice, and we appreciate the authors’ efforts in exploring this topic. However, during our review, we observed points that require clarification to better understand the presented finding: Patient Numbers in Table 1 In the study paper: The reported patient population underwent a sudden and significant reduction. This discrepancy was not sufficiently explained in the study.